cas 4101-30-8|| where to buy 2'-Amino-4',5'-dimethoxyacetophenone

製品名:2'-Amino-4',5'-dimethoxyacetophenone

IUPAC Name:1-(2-amino-4,5-dimethoxyphenyl)ethan-1-one

包装単位	有効在庫	価格（USD）
CM343560-25g	in stock	ȋƐȋ
CM343560-100g	in stock	ŸǠȋ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 4101-30-8 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:4101-30-8; 分子式:C10H13NO3; 融点:-; SMILESコード:CC(C1=CC(OC)=C(OC)C=C1N)=O; 密度:

: カタログ番号:CM343560; 分子量:195.22; 沸点:; MDL番号:MFCD00016646; 保管方法:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Cabozantinib; On August 21, 2023, Exelixis and Ipsen announced that the global phase 3 CONTACT-02 study of cabozantinib (Cabometyx ®) in combination with atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) met the primary endpoint of progression-free survival (PFS) in an interim analysis.
Prostate cancer is the fourth most common cancer worldwide and the second most common cancer among men. At present, the drugs approved for the treatment of CRPC are basically AR inhibitors or PARP inhibitors, and the combination therapy of Cabozantinib + Atezolizumab is expected to become a new treatment option for such patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.